ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.

Adjuvant Endocrine Therapy in Postmenopausal Patients With HR +ve BC With Good to Moderate Differentiation - ARNO (Arimidex + Nolvadex). Primary Treatment for 2 Years With Tamoxifen Thereafter Randomisation to: Tamoxifen 3 Years or Anastrozole 3 Years.

The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to receive tamoxifen.

Inclusion Criteria:

• Invasive mammary carcinoma after radical treatment, without prior chemo/hormone/radiation therapy.
• At least 6 lymph nodes examined.
• Good or intermediate tumour differentiation.
• <6 weeks before start of adjuvant therapy.
• Oestrogen or Progesterone positive

Exclusion Criteria:

• Premenopausal.
• Preoperative hormonal/antihormonal/radiation/cytoxic chemo. Second malignant tumour/status post second malignant tumour.
• In-situ/T4 carcinoma.
• Age >80 years.
• World Health Organisation performance index >3.
• Serious accompanying diseases